CN113135996A - 一种双特异抗体及其应用 - Google Patents

一种双特异抗体及其应用 Download PDF

Info

Publication number
CN113135996A
CN113135996A CN202011427863.9A CN202011427863A CN113135996A CN 113135996 A CN113135996 A CN 113135996A CN 202011427863 A CN202011427863 A CN 202011427863A CN 113135996 A CN113135996 A CN 113135996A
Authority
CN
China
Prior art keywords
ser
seq
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011427863.9A
Other languages
English (en)
Chinese (zh)
Inventor
屈向东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qiyu Biotechnology Shanghai Co Ltd
Original Assignee
Qiyu Biotechnology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qiyu Biotechnology Shanghai Co Ltd filed Critical Qiyu Biotechnology Shanghai Co Ltd
Priority to JP2023535529A priority Critical patent/JP7818838B2/ja
Priority to PCT/CN2021/094672 priority patent/WO2022121239A1/zh
Priority to EP21901953.6A priority patent/EP4261231A4/en
Priority to US18/256,679 priority patent/US20240043567A1/en
Publication of CN113135996A publication Critical patent/CN113135996A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202011427863.9A 2019-12-09 2020-12-09 一种双特异抗体及其应用 Pending CN113135996A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2023535529A JP7818838B2 (ja) 2019-12-09 2021-05-19 二重特異性抗体およびその適用
PCT/CN2021/094672 WO2022121239A1 (zh) 2019-12-09 2021-05-19 一种双特异性抗体及其应用
EP21901953.6A EP4261231A4 (en) 2019-12-09 2021-05-19 Bispecific antibody and application thereof
US18/256,679 US20240043567A1 (en) 2019-12-09 2021-05-19 Bispecific antibody and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019112532416 2019-12-09
CN201911253241 2019-12-09

Publications (1)

Publication Number Publication Date
CN113135996A true CN113135996A (zh) 2021-07-20

Family

ID=76809347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011427863.9A Pending CN113135996A (zh) 2019-12-09 2020-12-09 一种双特异抗体及其应用

Country Status (5)

Country Link
US (1) US20240043567A1 (https=)
EP (1) EP4261231A4 (https=)
JP (1) JP7818838B2 (https=)
CN (1) CN113135996A (https=)
WO (1) WO2022121239A1 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054701A (zh) * 2019-04-17 2019-07-26 中国医学科学院血液病医院（血液学研究所） 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CN113817065A (zh) * 2021-09-06 2021-12-21 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
WO2022121239A1 (zh) * 2019-12-09 2022-06-16 启愈生物技术(上海)有限公司 一种双特异性抗体及其应用
CN115246885A (zh) * 2022-06-30 2022-10-28 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
WO2022253248A1 (zh) * 2021-06-02 2022-12-08 启愈生物技术(上海)有限公司 抗cd3抗体变异体、融合蛋白及应用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023046116A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
CN116178546A (zh) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
CN116178565A (zh) * 2021-09-24 2023-05-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
CN116262786A (zh) * 2021-12-13 2023-06-16 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
WO2023138573A1 (zh) * 2022-01-21 2023-07-27 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
EP3083696B1 (en) * 2013-12-20 2018-02-14 F.Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
RU2689717C2 (ru) * 2014-01-08 2019-05-28 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Гетеродимерный белок il-15 и его применения
PL3235830T3 (pl) * 2014-12-19 2020-12-14 Jiangsu Hengrui Medicine Co., Ltd. Kompleks białkowy interleukiny 15 i jego zastosowanie
US10865230B2 (en) * 2016-05-27 2020-12-15 Altor Bioscience, Llc Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
WO2019006472A1 (en) * 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
AU2018334886B2 (en) * 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
SG11202010163QA (en) * 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (en) * 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
WO2019204646A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
CN113631580B (zh) * 2019-02-03 2024-07-02 上海宝济药业股份有限公司 抗her2的双特异性抗体及其应用
WO2020168554A1 (zh) * 2019-02-22 2020-08-27 武汉友芝友生物制药有限公司 改造的Fc片段，包含其的抗体及其应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054701B (zh) * 2019-04-17 2022-12-27 中国医学科学院血液病医院（血液学研究所） 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CN110054701A (zh) * 2019-04-17 2019-07-26 中国医学科学院血液病医院（血液学研究所） 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
WO2022121239A1 (zh) * 2019-12-09 2022-06-16 启愈生物技术(上海)有限公司 一种双特异性抗体及其应用
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
WO2022253248A1 (zh) * 2021-06-02 2022-12-08 启愈生物技术(上海)有限公司 抗cd3抗体变异体、融合蛋白及应用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
CN113817065A (zh) * 2021-09-06 2021-12-21 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
JP2024534982A (ja) * 2021-09-09 2024-09-26 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116178565A (zh) * 2021-09-24 2023-05-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
WO2023046116A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
CN116262786A (zh) * 2021-12-13 2023-06-16 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
WO2023138573A1 (zh) * 2022-01-21 2023-07-27 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物
CN115246885B (zh) * 2022-06-30 2023-10-24 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
CN115246885A (zh) * 2022-06-30 2022-10-28 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
CN116178546A (zh) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
WO2024077774A1 (zh) * 2022-10-13 2024-04-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用

Also Published As

Publication number Publication date
JP7818838B2 (ja) 2026-02-24
JP2023552851A (ja) 2023-12-19
US20240043567A1 (en) 2024-02-08
EP4261231A1 (en) 2023-10-18
WO2022121239A1 (zh) 2022-06-16
EP4261231A4 (en) 2024-11-13

Similar Documents

Publication Publication Date Title
CN113135996A (zh) 一种双特异抗体及其应用
JP2023552851A5 (https=)
JP7512210B2 (ja) 新規インターロイキン２およびその使用
JP2023174651A (ja) 新規インターロイキン２およびその使用
CN112552412B (zh) 一种包含TGF-β抑制剂、VEGF抑制剂和抗PDL1抗体的三功能融合蛋白
US10118964B2 (en) Construction and application of bispecific antibody HER2xCD3
CN111518213B (zh) 抗her2的双特异性抗体及其应用
CN112601546B (zh) Plap-car-效应细胞
CN113321738A (zh) 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
CN109415409A (zh) Flag标记的cd19-car-t细胞
JP7766672B2 (ja) ＴＧＦ－β ＲＩＩ突然変異体及びその融合タンパク質
WO2023046156A1 (en) Il-2 variants and fusion proteins thereof
JP2021533761A (ja) Ｏｘ４０結合性ポリペプチド及びその使用
CN104829728A (zh) 一种双特异性抗体her2xcd3的构建及应用
Richter et al. Receptor-targeted cancer therapy
CN113307879A (zh) 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN110437340A (zh) 双靶点识别可调控工程化免疫细胞的制备方法
CN109666074A (zh) 一种趋化因子受体cxcr5的用途
Hu et al. Epitope mapping and structural analysis of an anti‐ErbB2 antibody A21: molecular basis for tumor inhibitory mechanism
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
CN102492039A (zh) 全人源抗人her2单抗
CN118159568A (zh) 一种融合多肽及其用途
CN101948540B (zh) 抗egfr人源抗体mil27的设计及其应用
Hosseini-Ghatar et al. Epitope mapping of human HER2 specific mouse monoclonal antibodies using recombinant extracellular subdomains of HER2
CN120282988A (zh) 一种融合多肽及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination